Acute Kidney Injury in Patients Receiving Anti-Tuberculosis Treatment
##doi.readerDisplayName##:
https://doi.org/10.53778/pjkd92302キーワード:
acute kidney injury、 anti tuberculous treatment、 ATT、 Rifampicin、 Isoniazid、 AKI要旨
Although life-saving, anti-tuberculosis therapy (ATT) carries the risk of acute kidney injury (AKI), potentially complicating its management.
Methods: 102 subjects starting on ATT were followed for 2 months. Presence of AKI was documented with monitoring of kidney functions.
Results:
AKI was observed among 14.7% patients, predominantly affecting middle-aged males.
Conclusion:
Early recognition of AKI by monitoring for kidney function is crucial for reducing the risk of long-term sequelae of kidney failure among patients taking ATT.
ダウンロード
発行日
巻号
セクション
ライセンス
コピーライト (c) 2025 Madiha Mehmood, Dr Muhammad Anees

この資料のライセンスはCreative Commons 表示 - 非営利 4.0 国際 です。
